This article needs cleanup to meet MEpedia's guidelines.
This page needs additional references or sources for verification - multiple references need to be added. (2018)
S-adenosyl-methionine, also known as ADE-SD4, Ademetionine, S-adenosylmethionine, and abbreviated AdoMet or SAMe, is an amino acid derivative synthesized in the body that acts as the body's main methyl donor in many different metabolic reactions. It may become depleted with B-vitamin deficiency, chronic inflammation, and has been observed to decrease with age. When a person is deficient in
Theory[edit | edit source]
SAMe may help people with ME or CFS by restoring methyl donor levels, allowing methylation reactions to continue at a normal rate. If there is a deficiency of methyl donors in the central nervous system, SAMe supplementation might be expected to improve some brain function, or improve mood. Among many other synthetic reactions, SAMe aids in the synthesis of the neurotransmitters norepinephrine, dopamine, and serotonin.
Evidence[edit | edit source]
A small number of studies have been conducted in fibromyalgia patients which showed some positive effects when taking SAMe. The main positive effect has been described as a reduction in pain levels. However, Volkmann et al (2009) found no significant effect in a ten day trial of fibromyalgia patients.
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- "SAMe Uses, Benefits & Dosage - Drugs.com Herbal Database". Drugs.com. Retrieved Oct 15, 2019.
- Di Benedetto, P.; Iona, L. G.; Zidarich, V. (Feb 1, 1993). "Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia". Current Therapeutic Research. 53 (2): 222–229. doi:10.1016/S0011-393X(05)80250-4. ISSN 0011-393X.
- Jacobsen, S.; Danneskiold-Samsøe, B.; Andersen, R. B. (1991). "Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation". Scandinavian Journal of Rheumatology. 20 (4): 294–302. doi:10.3109/03009749109096803. ISSN 0300-9742. PMID 1925418.
- Tavoni, A.; Vitali, C.; Bombardieri, S.; Pasero, G. (Nov 20, 1987). "Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study". The American Journal of Medicine. 83 (5A): 107–110. doi:10.1016/0002-9343(87)90862-x. ISSN 0002-9343. PMID 3318438.
- Edwards, A. M.; Blackburn, L.; Christie, S.; Townsend, S.; David, J. (Jan 1, 2000). "Food Supplements in the Treatment of Primary Fibromyalgia: A Double-blind, Crossover Trial of Anthocyanidins and Placebo". Journal of Nutritional & Environmental Medicine. 10 (3): 189–199. doi:10.1080/13590840050134863. ISSN 1359-0847.
- Volkmann, H.; Norregaard, J.; Jacobsen, S.; Danneskiold-samsøe, B.; Knoke, G.; Nehrdich, D. (Jan 1, 1997). "Double-blind, Placebo-controlled Cross-over Study of Intravenous S-Adenosyl-L-Methionine in Patients with Fibromyalgia". Scandinavian Journal of Rheumatology. 26 (3): 206–211. doi:10.3109/03009749709065682. ISSN 0300-9742.
Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.